Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-06-03
2008-06-03
Kemmerer, Elizabeth C. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100, C514S012200
Reexamination Certificate
active
07381698
ABSTRACT:
The invention relates generally to methods for treating acute pancreatitis in patients. The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 4443434 (1984-04-01), Lien
patent: 4517309 (1985-05-01), Noda
patent: 5094837 (1992-03-01), Bis
patent: 6020310 (2000-02-01), Beck et al.
patent: 6143306 (2000-11-01), Donovan
patent: 6197746 (2001-03-01), Beck et al.
patent: 6261572 (2001-07-01), Donovan
patent: 6365593 (2002-04-01), Rusche et al.
patent: 6498143 (2002-12-01), Beck et al.
patent: 6534063 (2003-03-01), Fallon
patent: 2001/0018049 (2001-08-01), Sachs et al.
patent: 2003/0133906 (2003-07-01), Deviere et al.
Lightdale et al. Pediatrics. Effects of intravenous secretin on language and behavior of children with autism and gastrointestinal symptoms: a single-blinded, open-label pilot study. 2001; 108(5):1-5.
Jowell et al. Aliment Pharmacol Ther. A double-blind, randomized, dose response study testing the pharmacological efficacy of synthetic porcine secretin. 2000; 14:1679-1684.
Keim et al. Hepatogastroenterology. 1985; 32: 91-6.
FDA document found on FDA website at cder/foi/label/2002/21136s1Ib1.pdf, Secreflo (Trademark) secretin for Injection. NDA 21-136 & NDA 21-206, p. 5-13, published Aug. 29, 2002.
Manso et al. Peptides. 1989; 10: 255-260.
Renner et al. J. Clin. Invest. 1983; 72: 1081-1092.
Zieve L. Gastroenterology. Jan. 1964; 46: 62-7, esp. pp. 62-63.
Willemer and Adler, Int J Pancreatol. 1991; 9: 21-30.
“Off-Label” and Investigational Use of Marketed Drugs, Biologics and Medical Devices downloaded on Oct. 18, 2006 from fda.gov/oc/ohrt/irbs/offlabel.html.
AGA Council: Abstracts Submitted to the AGA, Gastroenterology, vol. 125, No. 2, pp. 605-607 (Aug. 2003).
AGA Council: Abstracts Submitted to the AGA, Gastroenterology, vol. 125, No. 2, pp. 605-607 (Aug. 2003), Printed from the Internet, “Gastroenterology Online”, at 5:20 p.m., Oct. 25, 2003.
Tympner, F., et al., “The Treatment of Chronic Recurrent Pancreatitis with Depot Secretin—a Preliminary Report,” Hepato-gastroenterology, vol. 33, pp. 159-162, 1986.
Renner, I., et al., “Partial Restoration of Pancreatic Function by Exogenous Secretin in Rats with Ceruletide-Induced Acute Pancreatitis,” Digestive Diseases and Sciences, vol. 31, No. 3, pp. 305-313, 1986.
Human Secretin Package Label (Apr. 5, 2004).
Fein Seymour H.
Purich Edward D.
Borgeest Christina
ChiRhoClin, Inc.
Garabedian Todd E.
Kemmerer Elizabeth C.
Wiggin and Dana LLP
LandOfFree
Methods for treatment of acute pancreatitis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment of acute pancreatitis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of acute pancreatitis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2808426